Bliss GVS Pharma Ltd (BLISSGVS) — Board Meeting | 28 September 2026 (4 announcements)

Bliss GVS Pharma announced the completion of Anupam Rasayan India's acquisition of 47.95% stake, making it a promoter, and appointed three new directors while accepting the resignation of Managing Director Narsimha Kamath effective September 28, 2026.

Bliss GVS Pharma announced on September 28, 2026 that Anupam Rasayan India Limited, via its subsidiary Mates Visa Consultancy Private Limited, acquired 5,09,84,595 shares representing 47.95% of the company, completing the transaction outlined in the May 23, 2026 share purchase agreement. The board appointed three new non-executive directors—Hetul Krishnakant Mehta, Amar Dilip Shah, and Pramod Badrinarayan Kasat—effective September 28, 2026, and accepted the resignation of Managing Director Narsimha Shibroor Kamath following the change in control. The board also approved a postal ballot notice for shareholder ratification of the new directors.

Bliss GVS Pharma announced that its board approved the reclassification of 22 outgoing promoters from the promoter group to the public category following the completion of a share purchase agreement and open offer on September 28, 2026, resulting in a reduction of promoter shareholding from 34.82% to 0.01% and full compliance with SEBI Listing Regulations.

Bliss GVS Pharma announced a board meeting on October 1, 2026, to consider establishing two employee stock option plans: the Senior Executive Employee Stock Option Plan 2026 and the Employee Stock Option Plan 2026. The meeting will be held via video conference at the company's registered office. This is part of routine governance and does not include financial results or operational updates.